查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601323

镰状细胞性贫血检测和筛检市场：按技术、年龄层和行业划分 - 2025-2030 年全球预测

Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography, Point-of-Care Tests), Age Group, Sector - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

镰状细胞性贫血检测和筛检市场2023年估值为94,395万美元，预计2024年将达到10,7069万美元，复合年增长率为13.51%，到2030年将达到22.2亿美元。美元。

镰状细胞性贫血的检测和筛检主要涉及透过血红蛋白电泳、高效液相层析(HPLC) 和基因检测等血液检测来识别镰状细胞疾病 (SCD) 和镰状细胞性状 (SCT)。早期诊断的必要性强调了对这些检查的必要性，以预防疼痛危象、中风和器官衰竭等严重併发症，从而改善患者的治疗结果和生活品质。应用范围从产前筛检到新生儿检测、带因者检测以及高风险个体的常规监测。最终用途范围包括需要准确和快速诊断能力的医疗机构、研究机构和诊断实验室。

主要市场统计
基准年[2023] 94395万美元
预测年份 [2024] 10.7069亿美元
预测年份 [2030] 2,293,220,000 美元
复合年增长率（%） 13.51%

市场成长受到遗传疾病意识增强、政府新生儿筛检计画倡议以及基因检测技术进步等因素的影响。由于高盛行率和不断增加的医疗基础设施投资，亚太和非洲的新兴市场提供了巨大的商机。对公司的调查包括透过伙伴关係关係扩大其地理影响力、投资于非侵入性检测的研究以及加强推广计划以提高意识。

然而，他们面临低收入地区医疗保健设施有限、先进诊断技术成本高昂以及缺乏训练有素的专业人员等挑战。监管障碍也可能阻碍新测试的快速推出。为了克服这些问题，创新领域包括开发具有成本效益的便携式测试解决方案以及改善远端医疗服务以服务偏远地区的人。

研究方向可能包括专注于遗传和分子诊断以及将 CRISPR 技术应用于确定性测试。持续的市场分析对于适应不断变化的监管条件和患者需求至关重要。这个市场的特点是快速的技术创新和地区不同的医疗保健能力，需要灵活的商业策略来应对这些挑战，同时利用成长机会。在这样一个动态的环境中，公司需要投资教育宣传活动、相关人员协作和适应性产品开发。

市场动态：快速发展的镰状细胞性贫血检测和筛检市场的关键市场洞察

供需的动态交互作用正在改变镰状细胞贫血检测和筛检市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球镰状细胞疾病流行
    • 政府持续努力支持诊断
    • 更多使用高效液相层析(HPLC) 检测镰状细胞
  • 市场限制因素
    • 镰状细胞性贫血相关的诊断与治疗问题
  • 市场机会
    • 开发深度学习框架，旨在对镰状细胞性贫血进行自动筛检
    • 越来越注重开发非侵入式、手持式和数位技术
  • 市场挑战
    • SCD 相关的临床异质性和併发症
    • 资源匮乏，缺乏熟练的临床实验室技术人员

波特五力策略工具驾驭镰状性贫血检测与筛检市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解镰状性贫血检测和筛检市场的外部影响

外部宏观环境因素在塑造镰状细胞贫血测试和筛检市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解镰状贫血检测和筛检市场的竞争格局

镰状细胞性贫血测试和筛检市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV 定位矩阵镰状贫血测试和筛检市场供应商的绩效评估

FPNV 定位矩阵是评估镰状细胞性贫血测试和筛检市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 镰状细胞疾病的全球盛行率
      • 政府继续努力支持诊断
      • 高效液相层析(HPLC) 检测镰状细胞疾病的重要用途
    • 抑制因素
      • 镰状细胞性贫血相关的诊断与治疗问题
    • 机会
      • 开发镰状学习框架，旨在对镰状细胞性贫血进行自动筛检
      • 更重视开发非侵入式、便携式和数位技术
    • 任务
      • SCD 相关的临床异质性和併发症
      • 缺乏资源和熟练的临床实验室技术人员
  • 市场区隔分析
    • 技术：血红蛋白电泳的持续进步，尤其是早期新生儿筛检
    • 部门：企业实验室处于创新和技术的前沿，提供全面的服务。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章镰状细胞性贫血检测与筛检市场：依技术分类

  • 血红素电泳
    • 等电聚焦
  • 高效液相层析（HPLC）
  • 就地检验
    • 侧流免疫检测
    • 纸本快速诊断

镰状细胞性贫血检测与筛检市场：依年龄组

  • 成人筛检
  • 新生儿筛检
  • 第1年至第25年

第 8 章按产业分類的镰状细胞性贫血检测与筛检市场

  • 企业实验室
  • 政府研究所
  • 私人实验室
  • 官民合作关係

第九章美洲镰状细胞性贫血检测与筛检市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区镰状细胞贫血检测与筛检市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲镰状性贫血检测与筛检市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 授予 300 万美元用于将血压药物重新用于 SCD 的研究
    • Mylab 推出独特的照护现场快速镰状细胞贫血检测
    • Lord's Mark Industries 与印度理工学院孟买分校合作在印度推广镰状细胞检测

公司名单

  • Biomedomics Inc.
  • HiMedia Laboratories
  • Pfizer Inc.
  • Silver Lake Research Corporation
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
  • Edvotek Inc.
  • Atlas Medical GmbH
  • Hemex Health
  • Quest Diagnostics Incorporated
  • CRISPR Therapeutics AG
  • Anamol Laboratories Pvt. Ltd.
  • Ulta Lab Tests, LLC
  • Bio-Rad Laboratories, Inc.
  • Bio Lab Diagnostics（I）Private Limited
  • PerkinElmer, Inc.
  • Bluebird bio, Inc.
  • Streck, Inc.
  • Maternova Inc.
  • Laboratory Corporation of America Holdings
  • Calibre Scientific, Inc.
  • PicnicHealth
  • Agios Pharmaceuticals, Inc.
Product Code: MRR-A339DAEFA37A

The Sickle Cell Anemia Testing & Screening Market was valued at USD 943.95 million in 2023, expected to reach USD 1,070.69 million in 2024, and is projected to grow at a CAGR of 13.51%, to USD 2,293.22 million by 2030.

Sickle Cell Anemia Testing and Screening encompasses a range of diagnostic techniques aimed at identifying sickle cell disease (SCD) and sickle cell trait (SCT), primarily through blood tests such as hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and genetic testing. The necessity of these tests is underscored by the need for early diagnosis to prevent severe complications like pain crises, stroke, and organ damage, thus improving patient outcomes and quality of life. Applications extend from prenatal screening to newborn and carrier testing and routine monitoring for individuals at risk. The end-use scope includes healthcare facilities, research institutions, and diagnostic laboratories that require precise and rapid diagnostic capabilities.

KEY MARKET STATISTICS
Base Year [2023] USD 943.95 million
Estimated Year [2024] USD 1,070.69 million
Forecast Year [2030] USD 2,293.22 million
CAGR (%) 13.51%

Market growth is influenced by factors such as increased awareness of genetic disorders, government initiatives for newborn screening programs, and technological advancements in genetic testing. Emerging markets in Asia-Pacific and Africa present substantial opportunities due to high prevalence rates and increasing healthcare infrastructure investments. Recommendations for businesses include expanding geographic presence through partnerships, investing in research for non-invasive testing methods, and enhancing outreach programs to raise awareness.

However, market growth faces challenges such as limited access to healthcare facilities in low-income regions, high costs of advanced diagnostic technologies, and lack of trained professionals. Regulatory hurdles can also impede the swift introduction of new testing methods. To overcome these, innovation areas include developing cost-effective, portable testing solutions and improving telehealth services to reach remote populations.

Research directions could focus on genetic and molecular diagnostics, exploring CRISPR technology for definitive tests. Continuous market analytics is crucial to adapt to changing regulatory landscapes and patient needs. The market, characterized by rapid technological change and varying regional healthcare capabilities, requires agile business strategies to address these challenges while capitalizing on growth opportunities. This dynamic environment calls for companies to invest in education campaigns, stakeholder collaborations, and adaptive product development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sickle Cell Anemia Testing & Screening Market

The Sickle Cell Anemia Testing & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Sickle Cell Disease Worldwide
    • Ongoing Government Initiatives to Support the Diagnosis
    • Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
  • Market Restraints
    • Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
  • Market Opportunities
    • Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
    • Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
  • Market Challenges
    • Clinical Heterogeneity and Complications Associated with SCD
    • Lack of Resources and Skilled Clinical Laboratory Workforce Shortages

Porter's Five Forces: A Strategic Tool for Navigating the Sickle Cell Anemia Testing & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sickle Cell Anemia Testing & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sickle Cell Anemia Testing & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sickle Cell Anemia Testing & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sickle Cell Anemia Testing & Screening Market

A detailed market share analysis in the Sickle Cell Anemia Testing & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sickle Cell Anemia Testing & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sickle Cell Anemia Testing & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Biomedomics Inc., HiMedia Laboratories, Pfizer Inc., Silver Lake Research Corporation, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, Edvotek Inc., Atlas Medical GmbH, Hemex Health, Quest Diagnostics Incorporated, CRISPR Therapeutics AG, Anamol Laboratories Pvt. Ltd., Ulta Lab Tests, LLC, Bio-Rad Laboratories, Inc., Bio Lab Diagnostics (I) Private Limited, PerkinElmer, Inc., Bluebird bio, Inc., Streck, Inc., Maternova Inc., Laboratory Corporation of America Holdings, Calibre Scientific, Inc., PicnicHealth, and Agios Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), and Point-of-Care Tests. The Hemoglobin Electrophoresis is further studied across Isoelectric focusing. The Point-of-Care Tests is further studied across Lateral Flow Immunoassay and Paper Based Rapid Diagnostics.
  • Based on Age Group, market is studied across Adult Screening, Newborn Screening, and Years 1 to 25.
  • Based on Sector, market is studied across Corporate Labs, Government Labs, Private Labs, and Public-Private-Partnerships.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
      • 5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
      • 5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
    • 5.1.2. Restraints
      • 5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
      • 5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
      • 5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
    • 5.2.2. Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Sickle Cell Anemia Testing & Screening Market, by Technology

  • 6.1. Introduction
  • 6.2. Hemoglobin Electrophoresis
    • 6.2.1. Isoelectric focusing
  • 6.3. High-performance Liquid Chromatography (HPLC)
  • 6.4. Point-of-Care Tests
    • 6.4.1. Lateral Flow Immunoassay
    • 6.4.2. Paper Based Rapid Diagnostics

7. Sickle Cell Anemia Testing & Screening Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult Screening
  • 7.3. Newborn Screening
  • 7.4. Years 1 to 25

8. Sickle Cell Anemia Testing & Screening Market, by Sector

  • 8.1. Introduction
  • 8.2. Corporate Labs
  • 8.3. Government Labs
  • 8.4. Private Labs
  • 8.5. Public-Private-Partnerships

9. Americas Sickle Cell Anemia Testing & Screening Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. USD 3 million awarded to study repurposing of blood pressure drug for SCD
    • 12.3.2. Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
    • 12.3.3. Lord's Mark Industries, IIT-Bombay partner to advance sickle cell testing in India

Companies Mentioned

  • 1. Biomedomics Inc.
  • 2. HiMedia Laboratories
  • 3. Pfizer Inc.
  • 4. Silver Lake Research Corporation
  • 5. Thermo Fisher Scientific Inc.
  • 6. Vertex Pharmaceuticals Incorporated
  • 7. Edvotek Inc.
  • 8. Atlas Medical GmbH
  • 9. Hemex Health
  • 10. Quest Diagnostics Incorporated
  • 11. CRISPR Therapeutics AG
  • 12. Anamol Laboratories Pvt. Ltd.
  • 13. Ulta Lab Tests, LLC
  • 14. Bio-Rad Laboratories, Inc.
  • 15. Bio Lab Diagnostics (I) Private Limited
  • 16. PerkinElmer, Inc.
  • 17. Bluebird bio, Inc.
  • 18. Streck, Inc.
  • 19. Maternova Inc.
  • 20. Laboratory Corporation of America Holdings
  • 21. Calibre Scientific, Inc.
  • 22. PicnicHealth
  • 23. Agios Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SICKLE CELL ANEMIA TESTING & SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 234. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023